Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good
Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still…
Immune Checkpoint Inhibitor Safe Both Before and After Mesothelioma Surgery
A report presented to an international gathering of lung cancer doctors shows an immune checkpoint inhibitor can make pre-surgery chemotherapy…
New Surgical Technique May Support Long-Term Peritoneal Mesothelioma Survival
One of the nation’s top mesothelioma doctors says long-term peritoneal mesothelioma survival is possible with a far-reaching new surgical technique.…
HITHOC for Pleural Mesothelioma: “Safe, Feasible and Effective”
A newly published study says a localized form of chemotherapy called HITHOC for pleural mesothelioma is “safe, feasible, and effective.”…
Study Reveals How TTFields and Chemotherapy Fight Mesothelioma
TTFields and chemotherapy offer one of the most potent combinations against malignant mesothelioma tumors. Now a new study reveals why…
Biomarkers in Pleural Effusions Can Improve Mesothelioma Diagnosis
Italian scientists say some newly identified biomarkers in pleural effusions are very good at ruling out mesothelioma in patients who…
Asia | International | Surgery | Treatments
Pleural Mesothelioma Patients are Stronger a Year After Surgery
Pleural mesothelioma patients can be stronger and have better lung function a year after surgery than in the days and…
Mesothelioma Update: Could New Form of Immunotherapy Help?
A new form of immunotherapy using a patient’s own cells is making headlines this month after a new study shows…
New Studies | Prognosis | Research | Surgery | Treatments
Physical Function Predicts Mesothelioma Surgery Outcomes
A patient’s level of physical function prior to mesothelioma surgery is a strong predictor of how well they will do…
Asbestos on Ships Still Poses a Mesothelioma Risk to Sailors
A new report warns that sailors are still at risk for malignant mesothelioma because of asbestos on ships – in…